Divisional patents: why revoking one patent rarely clears a product
A European patent application can be split into divisional applications that keep the parent's filing date and can be pursued for years after it. Originators use them to keep a product protected when a parent patent is revoked, and generics call it the divisional game. How divisionals work, what the EPO, the UPC, the UK courts and the European Commission have said about them in 2024–2026, with GSK's vilanterol and Novo Nordisk's semaglutide families as examples, and how to spot a family that is still alive.
Published 20 November 2026 · Last reviewed 20 November 2026 · MPA Business Services
What a divisional is
A European patent application can be split. While an application is still pending, its applicant may file a divisional application for any subject matter disclosed in it, and the divisional is treated as if it had been filed on the parent’s date, with the parent’s priority (Article 76 of the European Patent Convention). It also has the parent’s end date: a divisional cannot outlast its family’s 20-year term.
Two features make divisionals important for medicines:
- No deadline. Since April 2014 a divisional can be filed at any time as long as an earlier application in the family is still pending (Rule 36). A family filed in 2009 can still be producing new applications in 2026.
- Chains. A divisional can itself be divided, so a family can keep one application pending for most of its life. Each divisional must stay within what was disclosed in every application before it in the chain (G 1/05 and G 1/06), but its claims can be drafted with knowledge of what competitors are doing and of what the opposition division or a court has said about the parent.
The EPO will refuse a divisional that claims exactly what an already-granted family member claims (double patenting, G 4/19). Claims that differ even slightly, by a dose, a feature or a patient group, are not caught.
The divisional game
The phrase describes a pattern rather than a rule. A generic company spends years opposing or litigating a patent and wins. By then the family has one or more divisionals with similar claims, filed during the fight, still in examination or newly granted. Each must be attacked again, and each new grant can be asserted. If the patentee abandons a patent just before a decision, there may be no ruling at all on its validity, and nothing to stop a related divisional being granted.
For the people planning a launch, the effect is uncertainty. “The patent was revoked” may be true and still not mean the product is clear.
Two current examples
GSK’s vilanterol (Ellipta inhalers). GSK’s European patent 2 400 950, filed in 2009, claimed vilanterol at 25 µg and 50 µg once daily for asthma and COPD, the dose used in Relvar, Anoro and Trelegy Ellipta. Eight parties opposed it, among them Teva, Sandoz and Arven, alongside five filing through patent attorneys. In early 2026, after the Board of Appeal’s preliminary opinion said once-daily dosing was obvious, GSK withdrew its fallback requests and the patent was revoked without a reasoned decision on inventive step. Three divisionals from the same family, directed largely to the 25 µg formulation and in part to once-daily dosing, were reported as still opposed or in examination. The opponents argued that GSK’s handling of the family had prolonged uncertainty. The family’s term runs to 2029.
Novo Nordisk’s semaglutide dosing family. The EPO’s Boards of Appeal revoked the parent of Novo Nordisk’s once-weekly semaglutide dosing family in April 2025. A divisional, granted with similar claims, faces 18 oppositions, and a further divisional is in examination. When Sandoz brought a central revocation action against the divisional at the UPC, Novo Nordisk withdrew its approval of the patent text, which would lead the EPO to revoke it. On 22 October 2026 the Milan central division held that this did not automatically end Sandoz’s action: it can carry on and decide validity, and can order a proprietor not to withdraw its approval while the action is pending. A bare declaration that the dosing regimen was obvious, tied to no patent, is outside its jurisdiction, but it can declare that claims in the same family broad enough to cover the patent in suit would be invalid, which reaches divisionals still to come. The semaglutide case note has the detail.
How courts and authorities respond
The EPO examines each divisional on its own. Its tools are the added-matter rules for chains and the double-patenting bar, and an opposition decision on a parent does not bind the examination of a divisional.
The UPC has now said, in the semaglutide case, that a patentee cannot make a pending revocation action disappear by giving up the patent while keeping divisionals in reserve. In another Milan case in March 2026, between Neurocrine and Spruce, the court closed an action after the EPO revoked the patent but declined to make that conditional on an undertaking about divisionals, because divisionals do not automatically share their parent’s fate.
The UK courts can grant an “Arrow declaration”: a declaration that a product, or its use, was old or obvious at a given date. Because a valid patent cannot claim something that was obvious at its priority date, the declaration protects the product against any divisional in the family. The Court of Appeal confirmed in 2017, in the adalimumab dispute between Fujifilm Kyowa Kirin and AbbVie, that such declarations are available, but only where there is a good reason, not merely because applications are pending.
Competition law draws the outer line. In October 2024 the European Commission fined Teva €462.6 million for abusing its dominant position over Copaxone (glatiramer acetate). Part of the abuse was filing staggered divisionals and withdrawing them before they could be revoked, so that competitors faced a fresh patent each time and never got a final ruling. The Commission said that filing divisionals is legitimate in itself; the problem was using them to avoid decisions.
What to check
- The whole family, not one patent. On the EPO Register, open the family and list every member: granted, pending, withdrawn or revoked, with filing dates.
- Pending divisionals. A pending application can grant with new claims. Note what it claims now and what the parent’s description would support.
- Oppositions and their stage. A revoked parent with an opposed divisional is not the same as a revoked family.
- Withdrawals just before decisions. These leave no ruling to rely on.
- The end date. No divisional outlasts the family’s 20-year term, so the latest possible date is known from the parent’s filing date.
- The routes to certainty. In the UK, an Arrow declaration; at the UPC, a central revocation action plus, where justified, declaratory relief; at the EPO, opposing each divisional as it grants.
The explainer on clearing the path covers how those routes fit into a launch plan.
Sources
- European Patent Convention, Article 76: European divisional applications (EPO)
- Implementing Regulations to the EPC, Rule 36: European divisional applications (EPO)
- Enlarged Board of Appeal, G 4/19 (double patenting), 22 June 2021
- JUVE Patent, 12 March 2026: generics suspect GSK of playing 'divisional game' after EPO revocation
- Mewburn Ellis: the UPC view on the divisionals game (Milan, 22 October 2026)
- European Commission, Teva (Copaxone), Case AT.40588: summary decision (EUR-Lex)
- Cooley: stiff EU antitrust fine for misuse of patent system delaying rival pharma entry
- Court of Appeal, Fujifilm Kyowa Kirin v AbbVie [2017] EWCA Civ 1 (National Archives)
- Case note: semaglutide at the UPC, Milan says it can stop the divisional game
- Explainer: clearing the path and launching at risk
General information, not legal advice. The position for any particular product and country must be checked against the registers.
The position in every country, kept current
MPA Search holds the patent, SPC, licence and price position for products across the UK and Europe, with the reference to the original record. Book a free demonstration.